active substances, clopidogrel and acetylsalicylicacid (also known as aspirin) and is a ‘generic medicine’. This means that Clopidogrel/Acetylsalicylicacid Mylan contains the same active substance and works in the same way as a ‘reference medicine’ already authorised in the EU called DuoPlavin. Expand sectionCollapse sectionHow is Clopidogrel/Acetylsalicylicacid Mylan used?How does Clopidogrel Clopidogrel / Acetylsalicylicacid (Clopidogrel / Acetylsalicylicacid Viatris) (previously Clopidogrel / Acetylsalicylicacid Mylan) Skip to main contentAn official EU websiteHow do you know? We use cookies on this website. Essential cookies allow it to work properly. Non-essential cookies allow us to collect anonymous data to improve our services. You can opt out of non-essential cookies at any
Low-Dose acetylsalicylicacid (ASA) for the Prevention of Preeclampsia Skip to main content * .css-1yhta14{display:-webkit-box;display:-webkit-flex;display:-ms-flexbox;display:flex;-webkit-box-pack:start;-ms-flex-pack:start;-webkit-justify-content:flex-start;justify-content:flex-start;-webkit-align-items:center;-webkit-box-align:center;-ms-flex-align:center;align-items:center;position:relative
Stroke Best Practice Recommendations, seventh edition: acetylsalicylicacid forprevention of vascular events. CMAJ 2020 March 23;192:E302-311.Weitz JI, et al. Rivaroxaban or Aspirin for extended treatment of venous thromboembolism. N Engl J Med2017;376(13):1211-1222.Yasuda S, et al. Antithrombotic Therapy for Atrial Fibrillation with Stable Coronary Disease. N Engl J Med2019;381:1103-1113.Yusuf S, et AcetylsalicylicAcid (ASA) 1 of 6Acetylsalicylic Acid (ASA)Objective:To provide information on the use of acetylsalicylicacid in the prevention of vascular thromboembolicevents.Background:Acetylsalicylic acid (ASA) is well-established in the management of acute myocardial infarction and in thesecondary prevention of cardiovascular disease among both men and women, based on large
://www.uspreventiveservicestaskforce.org/Page/Document/RecommendationStatementFinal/aspirin-to-prevent-cardiovascular-disease-and-cancerWein T, et al, for the Heart and Stroke Foundation of Canada in collaboration with the Canadian StrokeConsortium. Canadian Stroke Best Practice Recommendations, seventh edition: acetylsalicylicacid forprevention of vascular events. CMAJ 2020 March 23;192:E302-311.Weitz JI, et al. Rivaroxaban AcetylsalicylicAcid (ASA) 1 of 6Acetylsalicylic Acid (ASA)Objective:To provide information on the use of acetylsalicylicacid in the prevention of vascular thromboembolicevents.Background:Acetylsalicylic acid (ASA) is well-established in the management of acute myocardial infarction and in thesecondary prevention of cardiovascular disease among both men and women, based on large randomizedtrials
Canadian Stroke Best Practice Recommendations, seventh edition: acetylsalicylicacid for prevention of vascular events Canadian Stroke Best Practice Recommendations, seventh edition: acetylsalicylicacid for prevention of vascular events ====================================================================================================================== * Theodore Wein * M. Patrice Lindsay POINTS * Acetylsalicylicacid is still strongly indicated for secondary prevention in patients who have had manifest cardiovascular, cerebrovascular or peripheral artery disease. * Acetylsalicylicacid (ASA) is no longer recommended for primary prevention in individuals without a history of symptomatic cardiovascular disease, stroke or peripheral artery disease; the harms of daily ASA use could
Pharmacokinetic Profile and Comparative Bioavailability of an Oral Fixed-Dose Combination of Metformin and AcetylsalicylicAcid (Aspirin). Patients with diabetes face a 2-4-fold greater cardiovascular risk compared to those without diabetes. Both metformin and acetylsalicylicacid (aspirin) treatment have demonstrated a significant reduction in this risk. This single-center, open-label, sequence randomized, 2 × 2 crossover, single-dose clinical trial evaluated the pharmacokinetics profile and comparative bioavailability of a novel oral fixed-dose combination (FDC) of metformin/acetylsalicylicacid (500/100 mg tablet) versus the reference mono-drugs administered concomitantly, metformin 500 mg tablet and acetylsalicylicacid 100 mg tablet, in 22 healthy Mexican adult volunteers under fasting
Predictors of treatment-response to caffeine combination products, acetaminophen, acetylsalicylicacid (aspirin), and nonsteroidal anti-inflammatory drugs in acute treatment of episodic migraine. To identify predictors of acute treatment optimization for migraine with "over-the-counter" (OTC) or prescription nonsteroidal anti-inflammatory drugs (NSAIDs) as well as other widely used OTCs including acetaminophen, caffeine combination products (CCP), and acetylsalicylicacid (ASA, aspirin) among people with episodic migraine and to develop models that predict treatment response to each class of OTCs. Efficacy of acute OTC medications for migraine varies greatly. Identifying predictors of treatment response to particular classes of medication is a step toward evidence-based personalized
, apixaban), direct thrombin inhibitor (dabigatran), warfarin, or another anticoagulants. All three included guidelines recommend the use of aspirin for venous thromboembolism prophylaxis in patients undergoing total hip or knee arthroplasty based on low quality evidence. Due to significant limitations of the evidence, interpretations of the findings should be taken with cautions.Files AcetylsalicylicAcidAcetylsalicylicAcid for Venous Thromboembolism Prophylaxis in Total Hip or Knee Replacement: A Review of Clinical Effectiveness and Guidelines AcetylsalicylicAcid for Venous Thromboembolism Prophylaxis in Total Hip or Knee Replacement: A Review of Clinical Effectiveness and Guidelines | CADTH Skip to main content * About * Collaboration/Outreach * Patient/Community * Careers * Contact
Safety and efficacy of early versus delayed acetylsalicylicacid after surgery for spontaneous intracerebral haemorrhage in China (E-start): a prospective, multicentre, open-label, blinded-endpoint, randomised trial Patients with non-traumatic intracerebral haemorrhage have a substantial risk of major adverse cardiovascular and cerebrovascular events, including ischaemic stroke, after surgery trial was done at eight stroke centres in China. Eligible patients were aged 18-70 years, undergoing surgery for the evacuation of spontaneous intracerebral haemorrhage, and had a high risk of postoperative ischaemic events. Using the minimisation method in an online randomisation system, patients were randomly assigned (1:1) to receive 100 mg acetylsalicylicacid once per day in either the early
AcetylsalicylicAcid Treatment in Patients With Sepsis and Septic Shock: A Phase 2, Placebo-Controlled, Randomized Clinical Trial. Platelets play a critical role in the inflammatory response and coagulation. We aimed to evaluate whether the use of acetylsalicylicacid (ASA) would reduce the intensity of organ dysfunction in septic patients. Randomized, blinded, parallel-group, placebo-controlled
Cessation vs. no cessation of acetylsalicylicacid preoperatively in laparoscopic totally extraperitoneal inguinal hernia repair (CAPTAIN): interim report from a multicentre, single-blind, randomised controlled trial. Given the increasing prevalence of antiplatelet agent use and the lack of high-quality evidence, the CAPTAIN trial aimed to investigate the safety and provide recommendations on continuing acetylsalicylicacid perioperatively in patients undergoing elective laparoscopic totally extraperitoneal inguinal hernia repair (LIHR). The CAPTAIN trial was a multicentre, surgeon blind, randomized controlled trial conducted from April 2016 to April 2023. Patients undergoing LIHR were eligible for inclusion. Participants were randomized to either the acetylsalicylicacid cessation group
Acetylsalicylicacid aggravates anaphylaxis in a PGE2-dependent manner. Acetylsalicylicacid (ASA) can exert proanaphylactic effects, but the extent of this phenomenon and its underlying mechanisms are undefined. Yet, low homeostatic prostaglandin E2 (PGE2) levels have been associated with anaphylaxis. In this study, we investigated whether the proanaphylactic effect of ASA is PGE2 dependent. We
Bevacizumab, atezolizumab and acetylsalicylicacid in recurrent, platinum-resistant ovarian cancer: the EORTC 1508-GCG phase II study. Treatment options for platinum-resistant ovarian cancer (PROC) are limited and new therapeutic strategies are urgently needed. This phase II, randomized, multicentre trial evaluated the safety and activity of the anti-PD-L1 antibody atezolizumab (atezo) combined with the VEGF-inhibitor bevacizumab (bev) and the irreversible cyclooxygenase inhibitor aspirin (ASA) in PROC. Patients were randomized to bev monotherapy 15 mg/kg (arm 1), atezo 1200 mg plus placebo (pbo)(arm 2), atezo plus ASA 320 mg/daily (arm 3), bev plus atezo plus pbo (arm 4) or bev plus atezo plus ASA (arm 5). Primary endpoint was progression-free survival at 6 months (PFS-6). Secondary objectives
Low-dose acetylsalicylicacid reduces local inflammation and tissue perfusion in dense breast tissue in postmenopausal women. One major risk factor for breast cancer is high mammographic density. It has been estimated that dense breast tissue contributes to ~ 30% of all breast cancer. Prevention targeting dense breast tissue has the potential to improve breast cancer mortality and morbidity mammographic density has been associated with increased inflammation. We investigated whether low-dose acetylsalicylicacid (ASA) affects local breast tissue inflammation and/or structural and dynamic changes in dense breasts. Postmenopausal women with mammographic dense breasts on their regular mammography screen were identified. A total of 53 women were randomized to receive ASA 160 mg/day or no treatment
Rationale and design for the randomized placebo-controlled double-blind trial studying the effect of single antiplatelet therapy (clopidogrel) versus dual antiplatelet therapy (clopidogrel/acetylsalicylicacid) on the occurrence of atherothrombotic event Antiplatelet therapy (APT) is the standard of care after endovascular revascularization (EVR) in patients with peripheral artery disease (PAD ). APT aims to prevent both major adverse cardiovascular events (MACE) and major adverse limb events (MALE). Nonetheless, the rates of MACE and MALE after EVR remain high. In coronary artery and cerebrovascular disease, dual APT (DAPT)compared to acetylsalicylicacid alone has proven to reduce MACE without increasing the risk of major bleeding when applied for a restricted number of weeks. However
Acetylsalicylicacid and dihydroartemisinin combined therapy on experimental malaria-associated acute lung injury: analysis of lung function and the inflammatory process. Severe malaria can cause respiratory symptoms, which may lead to malaria-acute lung injury (MA-ALI) due to inflammation and damage to the blood-gas barrier. Patients with severe malaria also often present thrombocytopenia , and the use of acetylsalicylicacid (ASA), a commonly used non-steroidal anti-inflammatory drug with immunomodulatory and antiplatelet effects, may pose a risk in regions where malaria is endemic. Thus, this study aimed to investigate the systemic impact of ASA and dihydroartemisinin (DHA) on ALI induced in mice by Plasmodium berghei NK65 (PbNK65). C57BL/6 mice were randomly divided into control (C
inflammation through low-dose acetylsalicylicacid (ASA, i.e., aspirin) is able to blunt the inflammatory response to experimental sleep restriction. 46 healthy participants (19F/27M, age range 19-63 years) were studied in a double-blind randomized placebo-controlled crossover trial with three protocols each consisting of a 14-day at-home monitoring phase followed by an 11-day (10-night) in-laboratory stay Effects of low-dose acetylsalicylicacid on the inflammatory response to experimental sleep restriction in healthy humans. Sleep deficiencies, such as manifested in short sleep duration or insomnia symptoms, are known to increase the risk for multiple disease conditions involving immunopathology. Inflammation is hypothesized to be a mechanism through which deficient sleep acts as a risk factor